

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

### CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page	number	(Without	Figures):	38	Rate:	6.2	CNY	per	ра	ıge
1 1 0		`	,						_	0

Editing Fee: 235.6 CNY

Figure count: 4 Figure handling time: 145 min Rate: 1 CNY per min

Editing Fee: 145 CNY

XML and PDF converting time: 60 min Rate: 1 CNY per min

Editing Fee: 60 CNY

Manuscript word count: 8653

**Total Editing Fee:** 440.6 CNY

Scientific Editor: Ze-Mao Gong

**Date of signature:** 11/1/2022 (month/day/year)

		Comments	
Item No.	Specific items for verification	Yes=[Y]	
		No= [N]	
	General Information of the Manuscript		
	Name of journal: World Journal of Diabetes		
	Manuscript NO.: 79128		
	Column: Minireviews		
1	Title: Advances in neovascularization after diabetic ischemia	[Y]	
	Authors: Yue Cai, Guang-Yao Zang, Yan Huang, Zhen Sun, Li-Li		
	Zhang, Yong-Jiang Qian, Wei Yuan and Zhong-Qun Wang		
	<b>Reviewer code:</b> 03547306, 06253286, 02461627, and 02461627		
	First decision: 2022-08-20 01:34		
2	Editorial Office's Comments	LVI	
	Science Editor: Remind Revision at 2022-08-28 08:18	[Y]	



# **Baishideng Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Company Editor-in-Chief: I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Diabetes, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide decomposable Figures (in which all components are movable and editable), organize them into a single PowerPoint file. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

**E-mail:** bpgoffice@wjgnet.com

		-
	Author(s) 2022. If an author of a submission is re-using a figure or	
	figures published elsewhere, or that is copyrighted, the author must	
	provide documentation that the previous publisher or copyright	
	holder has given permission for the figure to be re-published; and	
	correctly indicating the reference source and copyrights. For	
	example, "Figure 1 Histopathological examination by	
	hematoxylin-eosin staining (200 ×). A: Control group; B: Model	
	group; C: Pioglitazone hydrochloride group; D: Chinese herbal	
	medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL,	
	Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y,	
	Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine	
	formula on non-alcoholic fatty liver disease. World J Gastroenterol	
	2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published	
	by Baishideng Publishing Group Inc[6]". And please cite the	
	reference source in the references list. If the author fails to properly	
	cite the published or copyrighted picture(s) or table(s) as described	
	above, he/she will be subject to withdrawal of the article from BPG	
	publications and may even be held liable.	
3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is	[Y]
	not too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

		F3/3
	The authors' full family (sur)names and full/abbreviated first	[Y]
6	names are listed on the title page and are consistent with those	
	listed in the signed BPG Copyright License Agreement form.	
	The 'Author contributions' passage describes the specific	[Y]
	contribution(s) made by each author. The author's names are listed	
	in the following format: full family (sur)name followed by	
	abbreviated first and middles names.	
	e.g., "Wang CL and Liang L contributed equally to this work; Wang	
7	CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the	
	research study; Wang CL, Zou CC, Hong F and Wu XM performed	
	the research; Xue JZ and Lu JR contributed new reagents and	
	analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and	
	Wang CL, Liang L and Fu JF wrote the manuscript. All authors	
	have read and approve the final manuscript."	
	The 'Supported by' statement describes the source(s) of financial	[Y]
8	support and includes the corresponding identification number(s)	
	and program ID(s) if available, and contains no spelling errors.	
	The 'Corresponding author' passage provides the corresponding	[Y]
	author's full first and family (sur)names, abbreviated title (e.g., MD,	
9	PhD), affiliated institute's name and complete postal address	
	(including zip code) and e-mail (written in all lowercase), and	
	contains no spelling errors.	
	The Manuscript Tracking information ( <i>i.e.</i> , Received, Peer review	[Y]
10	started, First decision, Revised, Accepted, Article in press, and	
	Published online) are provided along with the corresponding editor	
	and date for each item, and contain no spelling errors.	
	The Abstract section is formatted according to the article-specific	[Y]
		1 + 1
11	style (structured <i>vs</i> unstructured) and word count thresholds, as	
	follows:	
	Commentary, Frontier, Diagnostic Advances, Medical Ethics,	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	Minireview, Review, Therapeutics Advances, and Topic Highlight:	
	Non-structured abstract that is no less than 200 words.	
	Field of Vision, Case Report and Letter to the Editor:	
	Non-structured abstract that is no less than 150 words.	
	Research articles: Structured abstract with subsections for AIM (no	
	more than 20 words); METHODS (no less than 80 words); RESULTS	
	(no less than 120 words); and CONCLUSION (no more than 26	
	words).	
	The 'Key words' list provides 5-10 keywords that reflect the main	[Y]
12	content of the study. The first letter of each keyword is capitalized,	
	and each keyword is separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The	[Y]
	name of the first author should be typed in bold letters; the family	
	(sur) name of all authors should be typed with the first letter	
	capitalized, followed by their abbreviated first and middle initials.	
13	For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	
	Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	
	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	
	Gastroenterol 2019; In press	
	The 'Core tip' provides a summary (less than 100 words) of the	[Y]
1.4	study that outlines the most innovative and important arguments	
14	and core contents of the paper and will serve to effectively attract	
	readers.	
	-	



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

**E-mail:** bpgoffice@wjgnet.com

	The 'INTRODUCTION' section clearly describes the relevant	[Y]
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
	exception of rare instances of seminal literature citations. All	
	technical terms and/or abbreviations are explained and/or defined,	
15	with the full name of abbreviations given upon first appearance in	
15	the text and the abbreviation presented in parentheses [i.e.,	
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	
	by the author(s). When weaknesses of previous studies are	
	described in the text to highlight the innovations related to the	
	current study, the information is presented carefully.	
	The 'MATERIALS AND METHODS' section clearly and accurately	[N]
16	describes all materials and methods used to obtain the data	
16	presented in the article and is adequate for a reader to repeat the	
	study.	
	The 'RESULTS' section concisely describes the observational and	[N]
	experimental results. Representative data and data that have	
	scientific significance are emphasized. Data is presented in either	
17	the text, a table or figure (i.e., chart, diagram, graph or image), but is	
	not repeated among each. Information presented in the tables and	
	figures clearly describes the trends, meaning, and inferences.	
	Results described in textual form are accurate, concise and clear.	
18	Statistical symbols are accurate. Statistical significance is expressed	[ N ]
	as ${}^{a}P$ < 0.05, ${}^{b}P$ < 0.01 ( $P$ > 0.05 usually does not need to be denoted).	
	If there are other series of $P$ values, $^{c}P < 0.05$ and $^{d}P < 0.01$ are used,	
	and a third series of $P$ values is expressed as $^{\rm e}P$ < 0.05 and $^{\rm f}P$ < 0.01.	
	Statistical data is expressed as mean $\pm$ SD or mean $\pm$ SE.	



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

**E-mail:** bpgoffice@wjgnet.com

		ENTI
	The 'DISCUSSION' section (1) describes the main purpose and	[N]
	hypothesis of the study; (2) summarizes the most important results;	
	(3) illustrates and explains the results (but does not simply repeat	
19	the data) and draws conclusions or inferences based on the results;	
1)	(4) points out the limitations of the study and their impact on the	
	results, as well as proposes further advice on future research	
	topic(s) or direction(s); and (5) describes the theoretical significance	
	and practical value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	[N]
	individuals or organizations for technical support (i.e., providing	
20	instrumentation, equipment or experimental materials, and/or	
20	assistance in experimental work), non-technical services (i.e., useful	
	inspiration, suggestions, guidance, or review), and/or any other	
	auxiliary work.	
21	The 'ARTICLE HIGHLIGHTS' section provides comments for	[N]
21	original articles in accordance with the specified format.	
	The 'REFERENCES' section lists the references in the Vancouver	[Y]
	style. This style uses Arabic numeral in-text citations based on the	
	order of the first appearance of a source in the text. For citations	
	where the author's name is indicated in the text, a superscript	
	number should be placed following the name (i.e, "Pang et al"). For	
22	citations where no author is indicated, a superscript number should	
	be placed at the end of the sentence. Respective examples are: "Ma[1]	
	reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high	
	sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the	
	reference number is described in the text; for example, "The	
	experimental method used has been described in reference [8]." The	
	style of reference citations in tables is the same as that in the text	
	(e.g., Pan et $al^{[2-5]}$ , please see reference [8]).	
-	1	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	,	
	Journal references have been verified to ensure that there are no	[Y]
	duplicate references and that the PMID numbers are correct. For	
	references not yet included in PubMed: the name of Chinese	
22	journals is spelled out using Chinese Pinyin, with the first letter of	
23	each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of	
	journals in other languages are listed according to indexing	
	information retrieved from Google. Book references are presented	
	with all the information relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as	[Y]
	follows:	
24	Commentary: no less than 50;	
24	Review: no less than 100;	
	Article: no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the	[Y]
25	manuscript type (e.g., Manuscript NoInstitutional review board	
	statement, Manuscript NoAnimal care and use statement, etc.).	
	The names of the peer reviewers and the scientific editor are present	[Y]
26	at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang	
	JL).	
	The order and numerical labeling of tables and figures is consistent	[Y]
	with their appearance and presentation in the text. Symbols in	
27	tables (e.g., +, -, $\times$ , $\div$ , *) correctly correspond to the definitions in the	
	footnotes. Only one legend is provided for each multi-panel figure	
	consisting of color graphs, black and white graphs, or line graphs	
	that depicts data of the same theme. For example: Figure 1	
	Pathological changes in atrophic gastritis tissue before and after	
	treatment. A:; B:; C:; D:; E:; F:	
20	Split pictures include flow charts, line graphs, histograms, and	[Y]
28	graphs including text. Unsplit pictures include meta-analysis	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

diagrams, PCR amplification curves, and survival curves.  The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.  The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional review board statement), and (7)	
according to the peer-reviewers' comments.  The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript Manuscr	
The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript Manuscript Manuscript Manuscript Manuscript	
the changes made to the manuscript.  The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript Manuscript NoManuscript NoManuscript NoManuscript NoManuscript NoManuscript NoManuscript NoManuscript NoClinical trial registration statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoManuscript NoManuscrip	
The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
NoReview; e.g., 870- Review).  The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoGrant application statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).  The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
NoAnswering reviewers; e.g., 870-Answering reviewers).  The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript	
approval form or document (file name: Manuscript	
· · · · · · · · · · · · · · · · · · ·	
NoInstitutional animal care and use committee statement), and (7)	
()	
Signed informed consent form(s) or document(s) (file name:	
Manuscript NoInformed consent statement).	
All authors signed the BPG Copyright license agreement form (file	
name: Manuscript NoCopyright license agreement; e.g.,	
870-Copyright license agreement).	
The language certificate provided by authors who are non-native	
speakers of English meets the BPG requirements (file name:	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

		1	
	Manuscript NoLanguage certificate; e.g., 870-Language certificate).		
	The photos licensed in the Agreement for Use of Personal Photos	[N]	
35	are consistent with those in the paper (file name: Manuscript		
33	NoAgreement for use of personal photos; e.g., 870-Agreement for		
	use of personal photos).		
	This document (Checklist of Responsibilities for Scientific Editors)	[Y]	
36	has been saved under the file name: manuscript NoScientific		
	editor work list (e.g., 870-Scientific editor work list).		
	A CrossCheck investigation (an effective tool for detecting unoriginal	[Y]	
	content, enabling our editors to preserve the journal's integrity and		
	the authors' copyright) has been performed for the manuscript via		
	the website: http://www.ithenticate.com/. The results document		
	contains the following information for the manuscript: "Name of		
37	journal", "Manuscript No.", "Columns", "Title" and "Author list".		
	The Figure of the <i>CrossCheck</i> results is saved in JPEG format (.jpg) at		
	$1440 \times 680$ pixel resolution. The PDF of the <i>CrossCheck</i> results has		
	been saved under the file name: manuscript No CrossCheck report		
	(e.g., 870-CrossCheck report). The Google searches have also been		
	performed to further ensure publication of original content.		
20	The text of the manuscript is typed in Book Antiqua font, 12 pt, with	[Y]	
38	1.5 line spacing.		
	The primary responsibilities of our scientific editors include carefully	y checking the	
	entire manuscript and all accompanying materials for: (1) error	s in snelling	
Responsibilities			
of scientific	grammar, punctuation and wording; (2) suitability of tables, figures, figure data and		
editors	legends; (3) accurate and appropriate presentation of symbols (e.g. +, -, ×, ÷, %, *) in		
Cartors	tables and figures; and (4) complete and comprehensive revision of the manuscript		
	according to the reviewers' comments.		



# Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

**E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

## **Publication** process

Manuscript reception and registration→Initial review by scientific editor→Peer review→End of peer review→First round of meeting evaluation→To be accepted→Revision by the author(s)→Second round of meeting evaluation→To be accepted/revised/rejected→Final review by the Editor-in-Chief (final quality control for academic content and language quality)→Final acceptance and charging of publication fee-Language editing-Production-Proofreading by scientific editor→Proofreading by deputy editor→Final review by Editor-in-Chief→Release of online open-access papers in electronic form on the BPG website-Release of online papers on PubMed Central-Delivery of high-quality PDF reprints to the author(s)→End of the publication process.